Immix Biopharma Secures Funding to Mid-2028, Targets March 2027 for Key NXC-201 Data
IMMX has more than doubled off its 52-week low of $1.87 on elevated volume (7.0× avg).
Summary
Immix Biopharma announced that its NXC-201 program is funded into mid-2028, providing significant financial runway. The company also expects to present one-year follow-up data for NXC-201 by March 2027, which will support a Biologics License Application (BLA) submission. This news follows the $150 million public offering priced yesterday, which secured the necessary capital. The extended cash runway reduces immediate funding concerns, and the clear timeline for clinical data and BLA submission provides a critical milestone for the drug's path to market.
At the time of this announcement, IMMX was trading at $8.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.7M. The 52-week trading range was $1.87 to $11.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.